Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.
复制标题
DOI：
10.1111/j.1365-2141.2010.08210.x
复制
发表时间：
2010-07
影响因子：
6.5
通讯作者：
Maloney DG
中科院分区：
文献类型：
--
作者：
Shustov AR;Gooley TA;Sandmaier BM;Shizuru J;Sorror ML;Sahebi F;McSweeney P;Niederwieser D;Bruno B;Storb R;Maloney DG
T细胞淋巴瘤(TCL)和自然杀伤细胞淋巴瘤(NKCL)患者的预后很差。这项研究考察了非清髓性预适应后异基因造血细胞移植(HCT)在这种情况下的作用。17例TCL或NKCL患者，包括3例首次完全缓解的患者，在2Gy全身照射加氟达拉滨后接受异基因HCT治疗。中位年龄57岁(范围18-73岁)。既往治疗的中位数为3次(范围1-7次)，6名患者(35%)之前的自体HCT失败，5名患者(29%)在同种异体移植时患有难治性疾病。移植后应用霉酚酸酯联合环孢素或他克莫司进行免疫抑制。存活患者平均随访3.3(0.3-8.0)年，3年总生存率和无进展生存率估计分别为59%和53%，3年无复发死亡和复发估计概率分别为19%和26%。65%的患者发展为2-4级急性移植物抗宿主病，53%的患者发展为慢性移植物抗宿主病。对于选择的TCL和NKCL患者，非清髓性预适应后的异基因HCT是一种有希望的抢救选择。这些结果表明，移植物抗T细胞淋巴瘤的活动对长期的疾病控制负责。
Patients with T-cell (TCL) and natural killer-cell lymphomas (NKCL) have poor outcomes. This study examined the role of allogeneic haematopoietic cell transplantation (HCT) after non-myeloablative conditioning in this setting. Seventeen patients with TCL or NKCL, including three patients in first complete remission, received allogeneic HCT after 2 Gy total-body irradiation and fludarabine. The median age was 57 (range, 18–73) years. The median number of prior therapies was 3 (range, 1–7), six patients (35%) had failed prior autologous HCT, and five patients (29%) had refractory disease at the time of allograft. Postgrafting immunosuppression was provided with mycophenolate mofetil with cyclosporine or tacrolimus. After a median follow-up of 3.3 (range, 0.3–8.0) years among surviving patients, the estimated probabilities of 3-year overall and progression-free survival were 59% and 53%, respectively, while the estimated probabilities of non-relapse mortality and relapse at three years were 19% and 26%, respectively. Sixty-five percent of patients developed grades 2–4 acute graft-versus-host disease and 53% of patients developed chronic graft-versus-host disease. Allogeneic HCT after non-myeloablative conditioning is a promising salvage option for selected patients TCL and NKCL. These results suggest that graft-versus-T-cell lymphoma activity is responsible for long-term disease control.
登录
查看更多内容
影响因子：
11.4
作者：
Fukushima, T;Miyazaki, Y;Tomonaga, M
通讯作者：
Tomonaga, M
影响因子：
20.3
作者：
Robinson, SP;Goldstone, AH;Schmitz, N
通讯作者：
Schmitz, N
影响因子：
45.3
作者：
Kyriakou, Charalampia;Canals, Carmen;Schmitz, Norbert
通讯作者：
Schmitz, Norbert
影响因子：
--
作者：
Kim, YH;Liu, HL;Hoppe, RT
通讯作者：
Hoppe, RT
影响因子：
45.3
作者：
Rodriguez, J;Munsell, M;Khouri, IF
通讯作者：
Khouri, IF